Eland Oil & Gas Regulatory News (ELA)

14 Apr 2008 12:40

Elan Corporation PLC14 April 2008 ELAN CORPORATION, PLC (the "Company") Annual Information Document for the period from 11 April 2007 up to andincluding 11 April 2008. The Company published its annual financial statementsin respect of the year ended 31 December 2007 on 1 April 2008. This Annual Information Document has been prepared by Elan Corporation, plc inaccordance with the provisions of Part 11 of the Prospectus (Directive 2003/71/EC) Regulations 2005 (S.I. No. 324 of 2005) and has been submitted to the IrishStock Exchange for filing with the Irish Financial Services Regulatory Authority(the Financial Regulator) in accordance with the Prospectus Rules issued by theFinancial Regulator. The Company is publishing this Annual Information Documentvia an RIS today and making it available on its website www.elan.com.The Companydoes not intend to rely solely on the Financial Regulator to publish the AnnualInformation Document. The information referred to in this document was up to date at the time it waspublished but some information may now be out-of-date. To avoid an unnecessarilylengthy document, information is referred to in this document rather thanincluded in full. 1. Announcements made via RNS, a regulatory information service All of the announcements listed below were published via RNS, a RegulatoryInformation Service and are available for viewing on the Irish Stock Exchangewebsite www.ise.ie. Date Announcement08/04/2008 Holding(s) in Company03/04/2008 Holding in Company01/04/2008 Elan Announces Dates for Upcoming Corporate Events and Filing of Annual Report for Year Ended December 31, 200731/03/2008 Total Voting Rights31/03/2008 Holding in Company11/03/2008 Director/PDMR Shareholding07/03/2008 Holding in Company04/03/2008 Holding in Company29/02/2008 Director/PDMR Shareholding29/02/2008 Holding in Company-Amendment29/02/2008 Total Voting Rights22/02/2008 Holding(s) in Company15/02/2008 Director/PDMR Shareholding15/02/2008 Holding in Company13/02/2008 Elan Reports Fourth Quarter and Full-Year 2007 Financial Results08/02/2008 Holding in Company07/02/2008 Holding in Company05/02/2008 Director/PDMR Shareholding05/02/2008 Elan Reports Share Sales under 10b5-1 Plan31/01/2008 Total Voting Rights22/01/2008 Elan Announces Webcast of Fourth Quarter and Full Year 2007 Financial Results18/01/2008 Director / PDMR Shareholding15/01/2008 FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease07/01/2008 Holding in Company07/01/2008 Biogen Idec and Elan Provide Update on Utilization, Safety and Total Patient Exposure of TYSABRI(R) in Patients with Multiple Sclerosis02/01/2008 Holding in Company02/01/2008 Holding in Company31/12/2007 Total Voting Rights24/12/2007 Elan and Transition Therapeutics Dose First Patient in Phase 2 Clinical Study of ELND005 (AZD-103) in Alzheimer's Disease24/12/2007 Elan and Wyeth Dose First Patient in North America in Phase 3 Program for Bapineuzumab (AAB-001) in Alzheimer's Disease19/12/2007 Blocklisting Interim Review18/12/2007 Elan to Present at the 26th Annual JP Morgan Healthcare Conference13/12/2007 Elan Update07/12/2007 Holding in Company06/12/2007 Holding in Company04/12/2007 Director/PDMR Shareholding30/11/2007 Total Voting Rights28/11/2007 Director/PDMR Shareholding16/11/2007 CHMP Adopts Negative Opinion on Appeal on European Application For natalizumab for the Treatment of Crohn's Disease09/11/2007 Holding in Company07/11/2007 Director/PDMR Shareholding31/10/2007 Total Voting Rights30/10/2007 Director/PDMR Shareholding29/10/2007 Elan Announces the Johnson & Johnson Pharmaceutical Research & Development Submission of a New Drug Application to the FDA for Paliperidone Palmitate Using Elan's Proprietary NanoCrystal(R) Technology25/10/2007 Elan Reports Third Quarter 2007 Financial Results15/10/2007 Elan Update15/10/2007 Elan and Biogen Idec Announce That FDA Will Extend Regulatory Review Period for TYSABRI(R) for Crohn's Disease11/10/2007 Biogen Idec and Elan Provide Update on Utilization and Safety of Tysabri(R) in Patients with Multiple Sclerosis11/10/2007 New TYSABRI(R) Data to Be Presented at the European Committee for Treatment and Research in Multiple Sclerosis09/10/2007 Elan Announces Webcast of Third Quarter 2007 Financial Results03/10/2007 Holding in Company28/09/2007 Total Voting Rights25/09/2007 Holding and Company21/09/2007 New Board Appointments20/09/2007 Director/PDMR Shareholding20/09/2007 Director/ PDMR Shareholding18/09/2007 Holding in Company14/09/2007 Director/PDMR Shareholding14/09/2007 Elan Announces New Board of Director Members07/09/2007 Interim Financial Statements07/09/2007 Treasury Shares Cancelled31/08/2007 Total Voting Rights22/08/2007 NICE Recommends TYSABRI(R) for Use in Highly Active Relapsing Remitting Multiple Sclerosis20/08/2007 TYSABRI(R) Demonstrates Significant Health-Related Quality-of-Life Improvements for Multiple Sclerosis Patients in Study Published in Annals of Neurology09/08/2007 Dr. Lars Ekman, President of Research and Development, Transitions to Board of Director Role02/08/2007 Holding in Company02/08/2007 Holding in Company01/08/2007 Director PDMR Shareholding01/08/2007 Joint FDA Advisory Committee Recommends Approval of TYSABRI(R) for the Treatment of Moderate to Severe Crohn's Disease31/07/2007 Total Voting Rights26/07/2007 Elan Reports Second Quarter 2007 Financial Results23/07/2007 TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis19/07/2007 Holding in Company10/07/2007 Elan Announces Webcast of Second Quarter 2007 Financial Results06/07/2007 Directors Disclosure03/07/2007 TYSABRI(R) Recommended by NICE for Use in Highly Active Relapsing Remitting Multiple Sclerosis in the Final Appraisal Determination29/06/2007 Total Voting Rights26/06/2007 Holding in Company13/06/2007 Blocklisting Interim Review29/05/2007 Elan and Biogen Idec Announce a FDA Advisory Committee Meeting to Review TYSABRI (R) for the Treatment of Crohn's Disease25/05/2007 Elan Holds Its AGM, All Resolutions Passed25/05/2007 Elan to Present at the Goldman Sachs 28th Annual Global Healthcare Conference21/05/2007 Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease14/05/2007 Holding in Company03/05/2007 Data Presented at the American Academy of Neurology's Annual Meeting Provide Update on Utilization and Safety of TYSABRI(R) in Patients with Multiple Sclerosis30/04/2007 Directors/PDMR Shareholding30/04/2007 Annual Information Document24/04/2007 Director/PDMR Shareholding24/04/2007 Elan Reports First Quarter 2007 Financial Results11/04/2007 Elan Announces Commencement of Exchange Offer for US$615 Million Aggregate Principal Amount of Notes 2. Documents filed with United States Securities and Exchange Commission The following documents have been filed with the US Securities and ExchangeCommission and are available on the Edgar website at http://www.sec.gov/edgar/searchedgar/webusers.htm. Date Filing Description31/03/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)31/03/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)31/03/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)28/02/2008 20-F Annual and transition report of foreign private issuers (Sections 13 or 15(d))14/02/2008 SC 13G/A (Amend)Statement of acquisition of beneficial ownership by individuals13/02/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)04/02/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)22/01/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)14/01/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)10/01/2008 SC 13G Statement of acquisition of beneficial ownership by individuals07/01/2008 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)21/12/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)18/12/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)13/12/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)16/11/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)29/10/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)25/10/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)15/10/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)11/10/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)11/10/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)09/10/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)28/09/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)14/09/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)10/09/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)10/09/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)22/08/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)20/08/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)09/08/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)01/08/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)26/07/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)23/07/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)19/07/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)09/07/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)03/07/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)29/05/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)24/05/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)21/05/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)03/05/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)24/04/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)10/04/2007 EFFECT Notice of Effectiveness10/04/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16)10/04/2007 424B3 Prospectus (Rule 424(b)(3))10/04/2007 6-K Report of foreign issuer (Rules 13a-16 and 15d-16) 3. Documents filed with the Registrar of Companies All of the documents listed below were filed with the Registrar of Companies inIreland on the dates indicated. Copies of documents filed with the Registrar ofCompanies are available from the Companies Registration Office at www.cro.ie. Date Filing Description09/04/2008 B5 Return of Allotments13/03/2008 B5 Return of Allotments18/02/2008 B6 Particulars of a contract relating to shares04/02/2008 B5 Return of Allotments04/02/2008 B5 Return of Allotments14/12/2007 B5 Return of Allotments26/11/2007 B5 Return of Allotments26/10/2007 B1 Annual Return26/10/2007 B1 Account details26/10/2007 B5 Return of Allotments15/10/2007 B10 Change in Director or Secretary28/09/2007 B7 Notice of consolidation, division, conversion27/09/2007 B5 Return of Allotments31/08/2007 G1 Ordinary Resolution authorising the issue of shares under section 2030/08/2007 G1P Special resolution30/08/2007 B5 Return of Allotments14/08/2007 B6 Particulars of a contract relating to shares24/07/2007 B5 Return of Allotments19/07/2007 B10 Change in Director or Secretary25/06/2007 B5 Return of Allotments29/05/2007 B5 Return of Allotments29/05/2007 B10 Change in Director or Secretary27/04/2007 B6 Particulars of a contract relating to shares11/04/2007 B5 Return of Allotments 4. Annual and Interim Report 2006 The Company's Annual Report and 20-F for the year ending 31 December 2007 whichwas filed with the Irish Stock Exchange on 1 April 2007, can be found on theCompany's website, as can the Interim Report for the 6 months ended 30 June 2007published on 7 September 2007. A copy of this Annual Information Document and copies of the documents referredto in it can be obtained from the Company Secretary at the Company's RegisteredOffice: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland. Enquiries: William Daniel Company Secretary +353 1 709 4000 14 April 2008 This announcement has been issued through the Companies Announcement Service of The Irish Stock Exchange. This information is provided by RNS The company news service from the London Stock Exchange